
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.

PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.

POMPANO BEACH, Fla., Sept. 03, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a

POMPANO BEACH, Fla., August 14, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the

Generates 29% sequential revenue growth, increasing to $7.9 million;Raises full-year 2026 revenue guidanceUplists to Nasdaq Capital Market PR Audio: POMPANO BEACH, FL, August 12, 2026

BROOMFIELD, Colo., August 12, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),

Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 29, 2026 – PRISM MediaWire (Press Release Service – Press

PR Audio: BROOMFIELD, Colo., July 07, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:

POMPANO BEACH, Fla., June 10, 2026 — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of

The new independent directors strengthen the Company’s board as seasoned executives bring deep expertise in life sciences commercialization, healthcare administration, and investment management PR Audio:
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850